BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 36000794)

  • 1. Patient-reported outcomes of a phase II neoadjuvant apalutamide (ARN-509) and radical prostatectomy in treatment of intermediate- to high-risk prostate cancer (NEAR) trial.
    Yang X; Allen JC; Aslim EJ; Tay KJ; Yuen SPJ; Kanesvaran R; Chua MLK; Chong TW; Ho SSH; Lee LS
    Int J Urol; 2022 Nov; 29(11):1322-1330. PubMed ID: 36000794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NEAR trial: A single-arm phase II trial of neoadjuvant apalutamide monotherapy and radical prostatectomy in intermediate- and high-risk prostate cancer.
    Lee LS; Sim AYL; Ong CW; Yang X; Ng CCY; Liu W; Rajasegaran V; Lim AMS; Aslim EJ; Ngo NT; Khor LY; Kanesvaran R; Allen JCJ; Tay KJ; Yuen JSP; Chong TW; Ho SSH; Teh BT; Chua MLK
    Prostate Cancer Prostatic Dis; 2022 Apr; 25(4):741-748. PubMed ID: 35091711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer.
    Devos G; Tosco L; Baldewijns M; Gevaert T; Goffin K; Petit V; Mai C; Laenen A; Raskin Y; Van Haute C; Goeman L; De Meerleer G; Berghen C; Devlies W; Claessens F; Van Poppel H; Everaerts W; Joniau S
    Eur Urol; 2023 Jun; 83(6):508-518. PubMed ID: 36167599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Editorial Comments to Patient-reported outcomes of a phase II neoadjuvant Apalutamide (ARN-509) and radical prostatectomy in treatment of intermediate- to high-risk prostate cancer (NEAR) trial.
    Kato M
    Int J Urol; 2022 Nov; 29(11):1330. PubMed ID: 36001637
    [No Abstract]   [Full Text] [Related]  

  • 5. Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study.
    Agarwal N; McQuarrie K; Bjartell A; Chowdhury S; Pereira de Santana Gomes AJ; Chung BH; Özgüroğlu M; Juárez Soto Á; Merseburger AS; Uemura H; Ye D; Given R; Cella D; Basch E; Miladinovic B; Dearden L; Deprince K; Naini V; Lopez-Gitlitz A; Chi KN;
    Lancet Oncol; 2019 Nov; 20(11):1518-1530. PubMed ID: 31578173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial.
    Saad F; Cella D; Basch E; Hadaschik BA; Mainwaring PN; Oudard S; Graff JN; McQuarrie K; Li S; Hudgens S; Lawson J; Lopez-Gitlitz A; Yu MK; Smith MR; Small EJ
    Lancet Oncol; 2018 Oct; 19(10):1404-1416. PubMed ID: 30213449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.
    Andre T; Amonkar M; Norquist JM; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt CJA; Smith D; Garcia-Carbonero R; Sevilla I; De La Fouchardiere C; Rivera F; Elez E; Diaz LA; Yoshino T; Van Cutsem E; Yang P; Farooqui M; Le DT
    Lancet Oncol; 2021 May; 22(5):665-677. PubMed ID: 33812497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact on quality of life of radical prostatectomy after initial active surveillance: more to lose?
    van den Bergh RC; de Blok W; van Muilekom E; Tillier C; Venderbos LD; van der Poel HG
    Scand J Urol; 2014 Aug; 48(4):367-73. PubMed ID: 24506062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial.
    Tosco L; Laenen A; Gevaert T; Salmon I; Decaestecker C; Davicioni E; Buerki C; Claessens F; Swinnen J; Goffin K; Oyen R; Everaerts W; Moris L; De Meerleer G; Haustermans K; Joniau S;
    BMC Cancer; 2018 Apr; 18(1):354. PubMed ID: 29606109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Standardising the Assessment of Patient-reported Outcome Measures in Localised Prostate Cancer. A Systematic Review.
    Ratti MM; Gandaglia G; Alleva E; Leardini L; Sisca ES; Derevianko A; Furnari F; Mazzoleni Ferracini S; Beyer K; Moss C; Pellegrino F; Sorce G; Barletta F; Scuderi S; Omar MI; MacLennan S; Williamson PR; Zong J; MacLennan SJ; Mottet N; Cornford P; Aiyegbusi OL; Van Hemelrijck M; N'Dow J; Briganti A;
    Eur Urol Oncol; 2022 Apr; 5(2):153-163. PubMed ID: 34785188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-cultural application of the Korean version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for patients with prostate cancer - EORTC QLQ-PR25.
    Park J; Shin DW; Yun SJ; Park SW; Jeon SS; Kwak C; Kwon TG; Kim HJ; Ahn H
    Oncology; 2013; 85(5):299-305. PubMed ID: 24217330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health-related quality of life in men after treatment of localized prostate cancer with external beam radiotherapy combined with (192)ir brachytherapy: a prospective study of 93 cases using the EORTC questionnaires QLQ-C30 and QLQ-PR25.
    Wahlgren T; Brandberg Y; Häggarth L; Hellström M; Nilsson S
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):51-9. PubMed ID: 15337539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality-of-life outcomes from the Prostate Adenocarcinoma: TransCutaneous Hormones (PATCH) trial evaluating luteinising hormone-releasing hormone agonists versus transdermal oestradiol for androgen suppression in advanced prostate cancer.
    Gilbert DC; Duong T; Kynaston HG; Alhasso AA; Cafferty FH; Rosen SD; Kanaga-Sundaram S; Dixit S; Laniado M; Madaan S; Collins G; Pope A; Welland A; Nankivell M; Wassersug R; Parmar MK; Langley RE; Abel PD
    BJU Int; 2017 May; 119(5):667-675. PubMed ID: 27753182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality of life of patients after retropubic prostatectomy - pre- and postoperative scores of the EORTC QLQ-C30 and QLQ-PR25.
    Bach P; Döring T; Gesenberg A; Möhring C; Goepel M
    Health Qual Life Outcomes; 2011 Nov; 9():93. PubMed ID: 22047686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perioperative Morbidity of Radical Prostatectomy After Intensive Neoadjuvant Androgen Blockade in Men With High-Risk Prostate Cancer: Results of Phase II Trial Compared to a Control Group.
    Ilario EN; Bastos DA; Guglielmetti GB; Murta CB; Cardili L; Cordeiro MD; Junior JP; Coelho RF; Nahas WC
    Clin Genitourin Cancer; 2023 Feb; 21(1):43-54. PubMed ID: 36428171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II open-label study investigating apalutamide in patients with biochemical progression after radical prostatectomy.
    Dirix P; Strijbos M; den Mooter TV; Liefhooghe N; Bruwaene SV; Uvin P; Ghysel C; Ost D; Schatteman P; Bral S; Engels B; den Begin RV; Otte FX; Roumeguere T; Palumbo S; Neybuch Y; Fonteyne V; Ost P; Dirix L
    Future Oncol; 2020 Jun; 16(16):1083-1189. PubMed ID: 32356465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality of life after robotic-assisted and laparoscopic radical prostatectomy: Results of a multicenter randomized controlled trial (LAP-01).
    Holze S; Lemaire E; Mende M; Neuhaus P; Arthanareeswaran VK; Truss MC; Minh Do H; Dietel A; Teber D; Stützel KD; Hohenfellner M; Rabenalt R; Albers P; Stolzenburg JU
    Prostate; 2022 Jun; 82(8):894-903. PubMed ID: 35254665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health-related Quality of Life at the SPARTAN Final Analysis of Apalutamide for Nonmetastatic Castration-resistant Prostate Cancer Patients Receiving Androgen Deprivation Therapy.
    Oudard S; Hadaschik B; Saad F; Cella D; Basch E; Graff JN; Uemura H; Dibaj S; Li S; Brookman-May SD; De Porre P; Bevans KB; Trudeau JJ; Small EJ; Smith MR
    Eur Urol Focus; 2022 Jul; 8(4):958-967. PubMed ID: 34479838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term health-related quality of life of prostate cancer survivors varies by primary treatment. Results from the PiCTure (Prostate Cancer Treatment, your experience) study.
    Drummond FJ; Kinnear H; O'Leary E; Donnelly ; Gavin A; Sharp L
    J Cancer Surviv; 2015 Jun; 9(2):361-72. PubMed ID: 25563819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coadministration of Apalutamide and Relugolix in Patients with Localized Prostate Cancer at High Risk for Metastases.
    Brown G; Belkoff L; Hafron JM; Saltzstein DR; Potdar R; Bhaumik A; Phillips J; McGowan T; Shore ND
    Target Oncol; 2023 Jan; 18(1):95-103. PubMed ID: 36472728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.